OmniAb, Inc. (OABI) Q3 Revenue $4.0M; Raises 2026 Outlook

What happened

OmniAb reported Q3 2026 revenue of $4.0M, up from $2.2M a year earlier, and a net loss of $15.7M. It raised 2026 revenue guidance to $35M–$39M and year-end cash outlook to $53M–$57M.

Confirmed

Global impact / market context

Higher revenue and a smaller net loss mean OmniAb is losing less money per dollar of sales, while trimmed operating costs extend how long its cash lasts. That reduces the chance it must raise outside money soon to fund research spending.

Analyst inference

A new Lilly ion channel deal adds up to $370M in potential milestone payments and royalties, which are payments tied to drug progress. Such deals can bring cash without selling shares, but the amounts arrive only if programs succeed.

Analyst inference

What to watch

1. 2026 revenue guidance is now $35M–$39M, raised from $32M–$36M, and year-end cash guidance is $53M–$57M, up from $49M–$53M. Confirmed
2. Management should be watched for whether it adds partner milestones or converts xPloration sales into repeating revenue, which would make sales less lumpy. Proposed
3. Investors may weigh milestone income from the Lilly deal against ongoing net losses, since milestones are uncertain and profit depends on partner drug programs advancing. Analyst inference

Evidence

• Original source link unavailable